Intramuscular Im Articles & Analysis

3 news found

Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)

ENA-001 is also being developed in an Intramuscular ("IM") formulation in partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Administration for Strategic Preparedness and Response in the U.S. ...

Oct. 3, 2022

ByEnalare Therapeutics Inc.

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

ENA-001 is also being developed in an Intramuscular (“IM”) Formulation in partnership with the Biomedical Advanced Research and Development Authority (“BARDA”) (contract number 75A50121C00044) for the potential use in patients experiencing drug overdose in a community setting and as a potential medical countermeasure for mass casualty ...

Aug. 9, 2022

ByEnalare Therapeutics Inc.

Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042

In 2021, Enalare formed a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of an intramuscular formulation (IM) for its lead compound, ENA-001, to treat life-threatening respiratory depression in both mass casualty and everyday community drug overdose situations. ...

Jan. 7, 2022

ByEnalare Therapeutics Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you